Involvement of RFC3 in tamoxifen resistance in ER-positive breast cancer through the cell cycle.

ABSTRACT: Since the establishment of the molecular subtyping system, ER positive breast cancer was considered to be the most prevalent type of breast cancer, and endocrine therapy was a very important solution. However, numerous studies have shown that the cell cycle plays a key role in the progression and metastasis of breast cancer. The present study showed that RFC3 was involved in the cell cycle through DNA replication. Furthermore, RFC3 expression was significantly higher in breast cancer-resistant cells than in parental cells, which correlated with the cell cycle. We confirmed these results by established drug-resistant cell lines for breast cancer, raw letter analysis and immunohistochemical analysis of primary and recurrent tissues from three ER+ breast cancers. In addition, analysis of the

SUBMITTER: Zhu J 

PROVIDER: S-EPMC10756131 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature